US 12,494,286 B1
Method of certifying a CBD product
Clifton D. Croan, Denver, CO (US); and William F. Graf, Denver, CO (US)
Assigned to ENIGAMI SYSTEMS, INC., Denver, CO (US)
Filed by Enigami Systems, Inc., Denver, CO (US)
Filed on May 14, 2019, as Appl. No. 16/412,335.
Application 16/412,335 is a continuation of application No. 14/739,723, filed on Jun. 15, 2015, granted, now 10,319,475.
Claims priority of provisional application 62/012,133, filed on Jun. 13, 2014.
This patent is subject to a terminal disclaimer.
Int. Cl. G16H 50/20 (2018.01); G06Q 10/10 (2023.01); G06Q 50/26 (2012.01)
CPC G16H 50/20 (2018.01) [G06Q 10/10 (2013.01); G06Q 50/26 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A method of certifying at least one CBD product comprising:
enlisting via a computer network a plurality of participants to report one or more experienced effects from their respective cannabidiol (CBD) usage;
receiving from a prospective participant via the computer network a jurisdiction where the prospective participant is located;
confirming that the prospective participant is located in a jurisdiction where use of cannabinoids is legal;
receiving from one or more of the plurality of participants via the computer network one or more self-assessment reports of one or more physical, emotional, or mental reported effects or one or more combination thereof from using at least one CBD product:
wherein the at least one CBD product has a CBD profile identifying an associated potency for the CBD that the at least one administered cannabinoid product contains; and
wherein the one or more self-assessment reports identify a user-selected-method by which the CBD product was administered;
processing the one or more self-assessment reports with a computer processor to determine that the CBD product affects a particular symptom or medical condition;
sending a certification report to a third party, wherein the certification report certifies to the third party that administration of the at least one CBD product by the user-selected-method affects the particular symptom or medical condition;
recommending an administration of the CBD product to a consumer to treat the particular symptom or medical condition;
administering the CBD product to the consumer to treat the particular symptom or medical condition.